Zobrazeno 1 - 10
of 1 389
pro vyhledávání: '"Programmed cell death-1"'
Autor:
Chunyan Lan, Huaiwu Lu, Lin Zhou, Kunlun Liao, Junxiu Liu, Zhiwen Xie, Haixi Liang, Guorong Zou, Ting Yang, Qin Xu, Xin Huang
Publikováno v:
Cancer Communications, Vol 44, Iss 6, Pp 654-669 (2024)
Abstract Background Camrelizumab plus apatinib have demonstrated robust antitumor activity and safety in patients with advanced cervical cancer (CLAP study; NCT03816553). We herein present the updated long‐term results of the CLAP study and explore
Externí odkaz:
https://doaj.org/article/0e9447bc32f74ee488112a4283effb55
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background and aims The prognosis of hepatocellular carcinoma (HCC) with macrovascular invasion(MaVI)is poor, and the treatment is limited. This study aims to explore the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC),
Externí odkaz:
https://doaj.org/article/f3fa0a110f02428290835a2bc1507750
Autor:
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐l
Externí odkaz:
https://doaj.org/article/143c8c3d40d4478d8742c856b4915c25
Autor:
Eleni-Kyriaki Vetsika, George E. Fragoulis, Maria Kyriakidi, Kleio-Maria Verrou, Maria G. Tektonidou, Themis Alissafi, Petros P. Sfikakis
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectivesProgrammed cell death protein-1 (PD-1) maintains peripheral immune tolerance by preventing T cell continuous activation. Aiming to understand the extent of PD-1 expression in inflammatory arthritis beyond its involvement with T cells, we as
Externí odkaz:
https://doaj.org/article/a5a2f00afe86473083a131ddd7e1ea56
Autor:
Yuki Sasaki, Kazuyuki Matsumoto, Akinobu Takaki, Takuya Adachi, Masahiro Takahara, Keita Ozato, Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Takashi Oda, Koichiro Tsutsumi, Kazuhiro Nouso, Kazuya Kariyama, Hiroaki Hagihara, Akio Moriya, Motoyuki Otsuka
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 8, Pp 1138-1147 (2024)
Background and Aims: Methods for predicting therapeutic response to immune checkpoint inhibitors in cancer therapy are in high demand. In patients with advanced hepatocellular carcinoma (HCC), atezolizumab (anti-programmed cell death-ligand 1 [PD-L1]
Externí odkaz:
https://doaj.org/article/5717d44ac54d405395840c4d75063afc
Publikováno v:
Tzu-Chi Medical Journal, Vol 36, Iss 3, Pp 340-348 (2023)
Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: PubMed, EMBASE, and th
Externí odkaz:
https://doaj.org/article/60c56a7e8675442a86e31385dfcfe2d6
Autor:
Jialiang Wang, Xiaoyu Zhang, Xinyi Ma, Dongmei Chen, Meina Cai, Lexin Xiao, Jing Li, Zexuan Huang, Yuehua Huang, Yifan Lian
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background Despite remarkable advancements in cancer immunotherapy, the overall response rate to anti-programmed cell death-1 (anti-PD-1) therapy in hepatocellular carcinoma (HCC) patients remains low. Our previous study has demonstrated the
Externí odkaz:
https://doaj.org/article/8ada1e098e7f4fa4a55d6cd2c964b19a
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 846-856 (2023)
Immune checkpoint inhibitors are increasingly being used to treat various malignancies. Despite their efficacy, they are known to potentially cause immune-related adverse effects, including dermatological manifestations. A rare cutaneous immune-relat
Externí odkaz:
https://doaj.org/article/9b4a7c1cb8034795b6be59458579dc93
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Introduction The optimal first-line immunotherapy regimen for advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression ≥ 50% remains unclear. Our aim is to determine the mo
Externí odkaz:
https://doaj.org/article/e0351466e20844bdacf90b847354cc82
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 4, Pp n/a-n/a (2024)
Abstract Objective Previous studies have shown that immune checkpoint inhibitors can improve the survival of patients with advanced non‐small cell lung cancer with KRAS mutations; however, there is a lack of comparisons between treatment regimens a
Externí odkaz:
https://doaj.org/article/55b74c33b25f4590a3c29a51711597c2